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Introduction
Orthopaedic registers are increasingly established in all
parts of the world and the large majority are used for
collection of data from total joint arthroplasties [5, 17,
18, 21, 26, 27].
The Swedish Hip Register still serves as the best
example for a well organised and functioning arthro-
plasty register. On the background of the Scandinavian
experience with implementation and organisation of
orthopaedic registries, the ﬁrst reports of a national
spine register also came from the northern parts of
Europe [33]. The Swedish lumbar spine registry is not
only the ﬁrst but also the only national spine register
that has reported its methodology and is continuously
reporting its results in the peer-reviewed literature.
Four key factors contribute to the success of the
Swedish endeavour: A national health service and
existing unique patient identiﬁers make possible the
identiﬁcation and follow-up of ‘migrating’ patients who
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Abstract In the discussion about the
rationale for spine registries, two
basic questions have to be answered.
The ﬁrst one deals with the value of
orthopaedic registries per se, con-
sidering them as observational
studies and comparing the evidence
they generate with that of rando-
mised controlled trials. The second
question asks if the need for regis-
tries in spine surgery is similar to
that in the arthroplasty sector. The
widely held view that randomised
controlled trials are the ‘gold stan-
dard’ for evaluation and that
observational methods have little or
no value ignores the limitations of
randomised trials. They may prove
unnecessary, inappropriate, impos-
sible, or inadequate. In addition, the
external validity and hence the abil-
ity to make generalisations about
the results of randomised trials is
often low. Therefore, the false con-
ﬂict between those who advocate
randomised trials in all situations
and those who believe observational
data provide suﬃcient evidence
needs to be replaced with mutual
recognition of their complementary
roles. The fact that many surgical
techniques or technologies were
introduced into the ﬁeld of spine
surgery without randomised trials or
prospective cohort comparisons
makes obvious an even increased
need for spine registries compared to
joint arthroplasty. An essential
methodological prerequisite for a
registry is a common terminology
for reporting results and a sophisti-
cated technology that networks all
participants so that one central data
pool is created and accessed. Rec-
ognising this need, the Spine Society
of Europe has researched and
developed Spine Tango, the ﬁrst
European spine registry, which can
be accessed under www.euro-
spine.org.
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change the centre of treatment, be it for reasons of
dissatisfaction with outcome or for simpler reasons like
relocation. Secondly, an established culture exists
among the orthopaedic community of naturally
reporting procedures and outcomes in registers.
Thirdly, the data collection technology employed is
easy to use and provides performance feedback to the
surgeons. Lastly, the initiator’s conviction of the three
most important aspects of any registry is ‘simplicity,
simplicity and simplicity’ (P. Fritzell, personal com-
munication).
Spine surgery and joint arthroplasty: the same needs?
The Scandinavian experience with the Christiansen total
hip prosthesis in the 1970s and Boneloc cement in the
mid-1990s underline the need for broad-based central
registration of implants and materials after they have
been marketed [23, 34]. In both cases, products were
released based on laboratory results without proper
assessment in the actual clinical arena. Thanks to the
Scandinavian post-market surveillance systems in place,
the inferiorly performing products were detected and
withdrawn.
Whenever new technologies enter the market, they
should be carefully surveyed and monitored since, as we
have seen in Scandinavia, neither laboratory testing nor
randomised controlled trials (RCTs) provide the ﬁnal
conclusive information and safety about the product
performance in the multitude of the diﬀerent clinical and
post-market settings, i.e. in reality. Although innova-
tions like surface replacement, navigation and minimal
invasive technologies are currently introduced into the
ﬁeld of total joint replacement, a less frequent intro-
duction of new inventions can be observed. Moreover,
the arthroplasty sector can beneﬁt from its long history
and the experiences gained by the enormous number of
treated patients over the past 40 years. In contrast, spine
surgery is a rather young orthopaedic subspecialty and
many questions regarding indications and optimum use
of treatments and technologies still remain open or have
only limited evidence [15]. Nevertheless, certain proce-
dures like spinal-fusion surgery are increasingly being
used. In the USA, the annual number of these types of
interventions rose by 77% between 1996 and 2001
whereas the number of total hip and knee replacements
only increased by 13–14% during the same interval [2].
Similarly, this trend can be observed by the development
of the US market for spinal implants and devices with
annual growth rates of 18–20% and an estimated overall
value of $2 billion [24]. Despite the widespread use of
spinal fusion, there are large geographic variations,
which suggest a poor level of professional consensus on
the indications [20]. This was conﬁrmed by systematic
reviews in 1999 and 2002, which concluded that there
was no acceptable evidence for many indications of
lumbar or cervical fusions [13, 16]. Similar to surgical
techniques, widely used technologies like pedicle screws
and intervertebral fusion cages were introduced without
randomised trials or prospective cohort comparisons.
Accordingly, opinion leaders in spinal surgery recom-
mend cautious approaches towards emerging new tech-
niques and devices, and closer scrutiny of spinal
implants and their use for unapproved indications. They
further suggest RCTs for new implants and indications
and rigorous post-market surveillance for adverse events
[10]. These proposals reﬂect that the need for outcomes
research in spinal surgery is probably higher than for
total joint arthroplasty. Whether this research is based
on RCTs or on observational data largely depends on
the research questions posed, the interventions and im-
plants under study, the patients included, and other
circumstantial factors.
The value of RCTs and observational data
After discussing the need for registration in spine
surgery, we have to look at the value of the infor-
mation that these data collections produce under ideal
circumstances. A view is widely held that RCTs are the
‘gold standard’ for evaluation and that observational
methods like prospective and retrospective cohort
studies and case control studies have little or no value.
Such a standpoint ignores the limitations of rando-
mised trials, which may prove unnecessary, inappro-
priate, impossible, or inadequate. Many of the
problems of conducting randomised trials could often,
in theory, be overcome, but the practical implications
for researchers and funding bodies mean that this is
often not possible. The false conﬂict between those
who advocate randomised trials in all situations and
those who believe observational data provide suﬃcient
evidence needs to be replaced with mutual recognition
of the complementary roles of the two approaches.
The attitude of ignoring the value of observational
data limits our potential to evaluate health care and
hence to improve the scientiﬁc basis of how to treat
individuals and how to organise services [3].
The much underestimated gulf between scientiﬁc
measurements based on RCTs and beneﬁt measure-
ments in the community was already recognised 30 years
ago. In 1972, Archie Cochrane introduced the term
‘eﬀectiveness’ to describe research results, and ‘eﬃ-
ciency’ to describe results obtained when a therapy is
applied in routine clinical practice in a deﬁned commu-
nity [7]. As opposed to a controlled research setting, a
vast variety of factors inﬂuence the treatment eﬃciency
such as screening, diagnosis, place of treatment, length
of stay, rehabilitation and optimum use of personnel and
materials.
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The limitation of RCTs: principles vs practice
The limitations of randomised trials can be derived from
either the inherent nature of the method (a limitation in
principle) or from the way trials are conducted (a limi-
tation in procedure). The importance of this distinction is
that while little can be done about the former, improve-
ments in the conduct of randomised trials could, in the-
ory, overcome some or all of the latter. As previously
mentioned, there are four main reasons for why obser-
vational methods are needed: experimentation may be
unnecessary, inappropriate, impossible, or inadequate.
Non-necessity
When the eﬀect of an intervention is dramatic, the likely
importance of unknown confounding factors is so small
that they can be ignored. Examples are penicillin for
bacterial infection, anaesthesia for surgical operations or
immobilisation of fractured bones.
Inappropriateness
Randomised trials may be inappropriate in four situa-
tions:
– They are often not large enough to detect infrequent
adverse outcomes.
– As a result of insuﬃcient study size, they have diﬃ-
culties evaluating interventions that are designed to
prevent rare events. This may not so much be the case
in orthopaedics than rather in accident prevention
schemes or in care of newborn children (e.g. correct
positioning to prevent sudden infant death syndrome).
– They have short observational and follow-up periods
and are very limited when the outcomes of interest are
far in the future as is, for example, the case in implant
loosening in total joint arthroplasty.
– They neutralise (with randomisation) the eﬀectiveness
of an intervention that depends on the subject’s active
participation, which, in turn, depends on the subject’s
beliefs and preferences.
Impossibility
In short, seven obstacles can be listed that researchers
have to face all too often:
– Reluctance or refusal of clinicians and key players to
participate [22, 31].
– Ethical objections [14, 36].
– There may be possible political obstacles if those who
fund and manage health services do not want their
policies studied [11].
– There have been examples where researchers met legal
obstacles in performing a randomised trial [6].
– Some interventions simply cannot be allocated on a
random basis [4].
– Contamination can occur if a clinician is expected to
provide care in more than one way. It is possible that
each approach will inﬂuence the way care is provided
to patients in the other arms of the study.
– The scale of the task confronting the research com-
munity: an immense number of health care interven-
tions are in use and most of them have several
components. It will only ever be practical to subject a
limited number of items to experimental evaluation
[12].
The exact nature of the obstacles will depend on the
cultural, political, and social characteristics of the situ-
ation and therefore, clearly, will vary over time.
Inadequateness
The external validity or possibility to generalise the
results of randomised trials is often low [25, 28]. The
results of drug trials can, in the main, be generalised to
other doctors and settings. In contrast, the outcome of
activities such as surgery, physiotherapy, psychotherapy
and community nursing may be highly dependent on the
characteristics of the provider, setting and patients. As a
consequence, unless care is taken in the design and
conduct of a randomised trial, a straightforward gener-
alisation of results may not be possible. There are three
reasons so as to why randomised trials in many areas of
health care may have low external validity:
– Health care professionals who participate may be
unrepresentative. They may have a particular interest
in the topic or be enthusiasts and innovators. The
setting may also be atypical, a teaching hospital, for
example.
– The patients who participate may be atypical. All
trials exclude certain categories of patients. Often the
exclusion criteria are so restrictive that the patients
who are eligible for inclusion represent only a small
proportion of the patients being treated in normal
practice [19, 35].
– The treatment may be atypical. Patients who partic-
ipate may receive better care, regardless of which arm
of the trial they are in [32].
This list of restrictions for generalising RCTs
compiled by Black in 1996 was recently complemented
by Rothwell [28] with a multitude of additional
restrictions that go beyond the scope of this article.
However, some of his recommendations make obvious
S54
the importance of this broadly neglected issue. Two of
them are:
– an increased consideration of the issue of external
validity in CONSORT [9] and Cochrane collabora-
tion guidelines [8],
– the International Committee of Medical Journal
Editors should require a new section for all primary
RCT reports or systematic reviews entitled ‘To whom
do these results apply?’.
Spine registers: not an RCT alternative,
but the observational adjunct
Observational studies like prospectively organised reg-
istries are no alternative to RCTs in terms of the level
of evidence they generate. Nevertheless, we must
appreciate the above listed problems and restrictions of
RCTs, especially their limited external validity, and
recognise observational data collections with a lower
level of evidence but a higher feasibility of being closer
to life, i.e. the circumstances in day-to-day clinical sit-
uations. If we manage to implement well-organised
registries with data of high validity and representa-
tiveness, we can take advantage of ﬁndings that are
easier to generalise and yet have an acceptable level of
evidence. If all spine surgeons contribute their bits and
pieces of information to a large data pool, a mosaic-
like picture will form. Within its structural pattern,
clinical interrelationships can occur. Rare adverse
events may suddenly show relationships to certain pa-
tient characteristics or variants in surgical technique
and assessment of long-term outcomes helps to sepa-
rate eﬀective from truly eﬃcient treatments. An essen-
tial methodological prerequisite is a common
terminology for reporting results and a sophisticated
technology that networks all participants so that one
central data pool is created and accessed. The Spine
Society of Europe has faced the challenge of such a
supranational endeavour [30] and recently reﬁned its
technical setup [1, 29] in order to cope with aspects of
patient and user conﬁdentiality. Information about the
Spine Tango project can be found on the SSE website
under www.eurospine.org—Spine Tango.
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